Harmony Biosciences (HRMY) Tops Q1 EPS by 25c

Harmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.88, $0.25 better than the analyst estimate of $0.63. Revenue for the quarter came in at $154.6 million versus the consensus estimate of $155.37 million.

Reiterates 2024 Net Product Revenue Guidance

Expect full year 2024 net product revenue of $700 million to $720 million

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus